Ropes and Gray: Novo Signs Hengrui Pharma Oral Obesity Drug Licensing Deal Up to $2.6 Billion
September 30, 2026
September 30, 2026
BOSTON, Massachusetts, Sept. 30 -- Ropes and Gray, a law firm, issued the following news:
* * *
Novo Signs Hengrui Pharma Oral Obesity Drug Licensing Deal up to $2.6 Billion
September 29, 2026
Novo has entered into a licensing agreement with Shanghai-based Hengrui Pharma for HRS-1596, a drug candidate with potential for once-weekly oral dosing for obesity and diabetes in a deal worth up to $2.6 billion. The transaction was announced on Septembe . . .
* * *
Novo Signs Hengrui Pharma Oral Obesity Drug Licensing Deal up to $2.6 Billion
September 29, 2026
Novo has entered into a licensing agreement with Shanghai-based Hengrui Pharma for HRS-1596, a drug candidate with potential for once-weekly oral dosing for obesity and diabetes in a deal worth up to $2.6 billion. The transaction was announced on Septembe . . .